MSSGX
Price
$18.05
Change
+$0.56 (+3.20%)
Updated
Aug 21 closing price
Net Assets
238.51M
WCMNX
Price
$15.06
Change
+$0.10 (+0.67%)
Updated
Aug 21 closing price
Net Assets
51.92M
Interact to see
Advertisement

MSSGX vs WCMNX

MSSGX vs WCMNX Comparison Chart in %
View a ticker or compare two or three
VS
MSSGX vs. WCMNX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MSSGX is a Hold and WCMNX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
MSSGX has more cash in the bank: 239M vs. WCMNX (51.9M). MSSGX (0.00) and WCMNX (0.00) have matching dividends . MSSGX was incepted earlier than WCMNX: MSSGX (37 years) vs WCMNX (7 years). WCMNX (2.04) is less costly to investors than MSSGX (1.19). MSSGX is a more actively managed with annual turnover of: 97.00 vs. WCMNX (89.00). WCMNX has a lower initial minimum investment than MSSGX: WCMNX (1000) vs MSSGX (1000000). WCMNX annual gain was more profitable for investors over the last year : 16.65 vs. MSSGX (7.12). WCMNX return over 5 years is better than : 1.76 vs. MSSGX (-38.20).
MSSGXWCMNXMSSGX / WCMNX
Total Expense Ratio1.001.2481%
Annual Report Gross Expense Ratio1.192.0458%
Fund Existence37 years7 years-
Gain YTD12.67211.144114%
Front LoadN/AN/A-
Min. Initial Investment10000001000100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets239M51.9M461%
Annual Yield % from dividends0.000.00-
Returns for 1 year7.1216.6543%
Returns for 3 years71.8931.41229%
Returns for 5 years-38.201.76-2,174%
Returns for 10 years27.34N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BITB41.822.37
+6.01%
Bitwise Bitcoin ETF
FGDL61.491.21
+2.00%
Franklin Responsibly Sourced Gold ETF
FBDC17.67N/A
-0.01%
FT Confluence BDC & SpecialtyFinacIncETF
WEA10.43-0.05
-0.48%
Western Asset Premier
BIS10.82-0.30
-2.70%
ProShares UltraShort Nasdaq Biotech